The Claim
Among adults taking atorvastatin, carriers of the SLCO1B1 rs4149056 variant have a twofold increased risk of developing statin-associated muscle symptoms (SAMS), with higher rates observed in females and individuals of Arab ethnicity.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Adults taking atorvastatin who carry the SLCO1B1 rs4149056 genetic variant experience twice the rate of muscle symptoms compared to non-carriers, and this effect is higher in females and individuals of Arab ethnicity.
See the scientific wording
Among adults taking atorvastatin, carriers of the SLCO1B1 rs4149056 variant have a twofold increased risk of developing statin-associated muscle symptoms (SAMS), with higher rates observed in females and individuals of Arab ethnicity, suggesting that genetic and demographic factors interact to influence muscle-related adverse effects in this population.
A genetic change in the liver reduces how well it takes up atorvastatin, so more of the drug stays in the blood. This higher blood level lets more drug enter muscle cells, where it damages the energy-producing parts of the cells, causing muscle pain and weakness.
What the research says
1 studyPeople taking atorvastatin who have a specific gene variant are about twice as likely to get muscle pain, especially if they’re women or of Arab descent — and this study found exactly that in a real group of patients.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.